Transgene Logo

Transgene

TNG | PA

Overview

Corporate Details

ISIN(s):
FR0005175080
LEI:
969500PDJW8N0FSGGK69
Country:
France
Address:
400 BOULEVARD GONTHIER D'ANDERNACH, 67400 ILLKIRCH-GRAFFENSTADEN
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Transgene is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. A pioneer in viral vectors engineering, we have one ambition: design innovative treatments in the fight against cancer. Our approach uses the mechanisms of the immune response to enable the patient’s body to fight against disease.

Social Media

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-09 17:45
Board/Management Information
Transgene nomme une experte de l’industrie pharmaceutique, Emmanuelle Quilès, e…
French 387.4 KB
2025-07-09 17:45
Board/Management Information
Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Di…
English 255.1 KB
2025-06-19 08:00
Legal Proceedings Report
Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial …
English 310.5 KB
2025-06-19 08:00
Legal Proceedings Report
Transgene finalise la sélection initiale de patients pour la partie Phase II de…
French 304.7 KB
2025-06-13 08:30
Report Publication Announcement
Transgene participera à plusieurs rencontres avec des acteurs clés de la biotec…
French 304.7 KB
2025-06-13 08:30
Report Publication Announcement
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
English 277.0 KB
2025-06-03 08:00
Regulatory News Service
Transgene organise un webinaire sur les résultats positifs de TG4050 dans les c…
French 269.2 KB
2025-06-03 08:00
Report Publication Announcement
Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presente…
English 282.5 KB
2025-06-01 19:15
Regulatory News Service
Transgene et NEC présentent une survie sans récidive durable, accompagnée d’une…
French 378.8 KB
2025-06-01 19:15
Earnings Release
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Re…
English 394.4 KB
2025-05-22 17:45
Regulatory News Service
Transgene présente des données de survie sans récidive à 24 mois sur l’ensemble…
French 378.1 KB
2025-05-22 17:45
Regulatory News Service
Transgene to Present 24-month Disease-Free Survival Data from All Patients in P…
English 412.3 KB
2025-05-15 17:45
Post-Annual General Meeting Information
Assemblée Générale Mixte de Transgene du 15 mai 2025
French 315.4 KB
2025-05-15 17:45
Post-Annual General Meeting Information
Transgene's Combined General Meeting of May 15, 2025
English 285.9 KB
2025-04-24 17:45
Business and Financial Review
Transgene Provides Business and Financial Update for Q1 2025
English 310.4 KB

Insider Transactions

Date Insider Name Position Type Shares Value
2024-07-30 N/A Other Other 30,898,876 32,999,999.57 EUR
2023-05-26 N/A Other Buy 29,325 N/A

Peer Companies

Company Country Ticker View
ANIMALCARE GROUP PLC Logo ANIMALCARE GROUP PLC United Kingdom ANCR
Annexin Pharmaceuticals AB Logo Annexin Pharmaceuticals AB Sweden ANNX
Apontis Pharma AG Logo Apontis Pharma AG Germany APPH
Aptahem AB Logo Aptahem AB Sweden APTA
Arctic Bioscience Logo Arctic Bioscience Norway ABS
ArcticZymes Technologies Logo ArcticZymes Technologies Norway AZT
argenx SE Logo argenx SE Netherlands (Kingdom of the) 1AE
ARIX BIOSCIENCE PLC Logo ARIX BIOSCIENCE PLC United Kingdom ARIX
AroCell AB Logo AroCell AB Sweden AROC
Arterra Bioscience Logo Arterra Bioscience Italy ABS